Summary & Overview
CPT 0189U: Navigator GYPA Sequencing for MNS Blood Group Antigens
CPT code 0189U denotes a Proprietary Laboratory Analyses (PLA) test — the Navigator GYPA Sequencing assay from Grifols Immunohematology Center — which sequences genes to determine MNS blood group antigens. This molecular immunohematology test is clinically relevant for reducing adverse blood–type incompatibility events in transfusion medicine, organ transplantation, and perinatal care. Its PLA designation means the code maps to a single manufacturer-specific assay rather than a class of tests, which affects coding, billing, and payer coverage practices nationally.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage patterns, clinical context for use, and coding considerations tied to PLA-designated sequencing assays.
Readers will learn: the clinical role of the Navigator GYPA Sequencing test in identifying MNS antigens; how the PLA status of 0189U influences billing and payer interactions; expected sites of service and specimen requirements; and where to find relevant policy inputs and benchmarks. Data not provided in the input (such as specific coverage policies, associated taxonomies, ICD-10 mappings, or pricing benchmarks) are noted as unavailable.
Billing Code Overview
CPT code 0189U is a Proprietary Laboratory Analyses (PLA) code reported for the Navigator GYPA Sequencing test from Grifols Immunohematology Center. The test analyzes specific gene sequences that indicate MNS blood group antigens, which can inform compatibility in blood transfusions, organ transplants, pregnancy, and newborn care.
Service type: Genetic sequencing for immunohematology (proprietary laboratory test)
Typical site of service: Clinical laboratory (specimen such as blood)
Clinical & Coding Specifications
Clinical Context
A patient scheduled for blood product transfusion or a pregnant patient with a history of alloimmunization is referred for molecular blood group genotyping. The specimen (typically a whole blood sample) is collected in a clinical laboratory or hospital phlebotomy area and sent to the reference lab (Grifols Immunohematology Center) performing the proprietary Navigator GYPA Sequencing test. The laboratory receives the specimen, verifies patient identifiers and clinical indication, performs DNA extraction and targeted sequencing of the GYPA gene regions specified by the test, and interprets sequence variants that define MNS blood group antigens. Results are reported to the ordering transfusion medicine physician, obstetrician, or blood bank specialist to guide selection of compatible blood products and to minimize risk of hemolytic transfusion reactions, hemolytic disease of the fetus/newborn, or alloimmunization during future transfusions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no specific modifier applies and service is billed normally. |
11 | Office or other outpatient service (primary) | Use when this test is the primary service during an outpatient encounter. |